Dyslipidemia is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL), resulting from diet, tobacco and alcohol use, sedentary lifestyle, or genetic factors such as familial hypercholesterolemia. It is a leading cause of cardiovascular disease and may contribute to severe complications.

CME Activities

News Digest

article

Atherosclerosis/Thrombosis

article

Atherosclerosis/Thrombosis

article

Atherosclerosis/Thrombosis

Expert Highlights and Perspectives

Lipid-Lowering in Women: Additional Perspectives

FACULTY SPOTLIGHT
Erin D. Michos, MD, MHS
Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Eugenia Gianos, MD
Watch Drs. Michos and Gianos recap the symposium at the 2023 Women Masterclass, as well as discuss additional clinical pearls on lipid-lowering therapy in women (recorded September 2023).

Additional Insights on the Spectrum of LDL-C Lowering therapies and Efficacy in Women

FACULTY SPOTLIGHT
Payal Kohli, MD
Watch as Dr. Kohli discusses additional perspectives on statin and non-statin therapies and what can clinicians do better to lower LDL-C and optimize outcomes in women (recorded September 2023).

Patient Story: Agnes' Journey

FACULTY SPOTLIGHT
Agnes Czuchlewski
Agnes Czuchlewski, WomenHeart Patient Champion
Agnes Czuchlewski, patient champion with WomenHeart, discusses her journey about living with heart disease and challenges she experienced in getting diagnosed and treated (recorded September 2023).

Patient Story: Take Home Messages for Clinicians

FACULTY SPOTLIGHT
Agnes Czuchlewski
Agnes Czuchlewski, WomenHeart Patient Champion
Watch as patient champion Agnes Czuchlewski shares some important messages that she would like for clinicians to consider when taking care of women with cardiovascular disease or cardiovascular risk (recorded September 2023).

Recap of Major Lipid-Lowering Trials at 2023 ACC

FACULTY SPOTLIGHT
Christie M. Ballantyne, MD
Christie Ballantyne, MD
Erin D. Michos, MD, MHS
Erin Michos, MD

Watch Dr. Ballantyne and Dr. Michos discuss key trials in lipid lowering presented at 2023 ACC, including CLEAR Outcomes with bempedoic acid, a phase 2 trial with oral PCSK9 inhibitor MK-0616, as well as their potential implications. Recorded March 10, 2023

Lipid Management in the Post-ACS Patient

FACULTY SPOTLIGHT
Christie M. Ballantyne, MD
Christie Ballantyne,
MD
Erin D. Michos, MD, MHS
Erin Michos,
MD
Salim S. Virani,
MD

Watch Drs. Ballantyne, Taub, and Virani discuss some practical pearls about the optimization of lipid-lowering therapy in patients with a recent MI or an acute coronary syndrome (ACS) event. They discuss suboptimal LDL-C levels in these patients, reasons for these gaps, and how to lower LDL-C levels early and effectively with evidence-based therapies in order to minimize the risk of recurrent events. (Recorded June 20, 2022). 

Expert Perspectives and Recent Developments in LDL-C Lowering

FACULTY SPOTLIGHT
Christie M. Ballantyne, MD
Christie Ballantyne,
MD
Erin D. Michos, MD, MHS
Erin Michos,
MD
Joseph Saseen, PharmD
Joseph Saseen,PharmD

Watch Drs. Ballantyne, Michos, and Saseen discuss some practical pearls about recent developments in LDL-C lowering. They discussed combination therapy and constantly evolving lipid therapy, including data about monoclonals, and siRNA, also presented at 2022 AHA meeting. Recorded on Dec. 14, 2022.

CMHC Annual 2021 Lipid Management Panel

FACULTY SPOTLIGHT
Robert Eckel,
MD
Christie M. Ballantyne, MD
Christie Ballantyne,
MD
Matthew J. Budoff, MD
Matthew Budoff,
MD

CMHC Chairs Christie Ballantyne, MD and Robert Eckel, MD, as well as CMHC faculty Matthew Budoff, MD recap the lipid sessions presented at the 16th Annual CMHC, including perspectives and clinical pearls on ASCVD risk assessment, residual ASCVD risk, and ASCVD management and prevention.

Lipid Management in Very High-Risk Patients Post-MI: Expert Perspectives with Drs. Taub, Desai, Shapiro

FACULTY SPOTLIGHT
Pam Taub, MD
Pam Taub,
MD, FACC
Nihar R. Desai,
MD, MPH, FACC
Michael D Shapiro DO
Michael D. Shapiro,
DO, MCR, FACC, FAHA

Watch Drs. Taub, Desai, and Shapiro discuss some additional perspectives on the management of very high-risk, including:

  • The safety of very low LDL-C
  • Concerns with statins and new-onset diabetes and how to address overall patient concerns about lipid-lowering therapy
  • Residual ASCVD risk beyond LDL-C

Drug Pipeline

LDL-C Lowering

Lp(a) lowering

Triglyceride lowering

ASCVD = atherosclerotic cardiovascular disease; | HTG = hypertriglyceridemia; | siRNA = small interfering RNA | ASCVD = atherosclerotic cardiovascular disease; | CVD = cardiovascular disease | HeFH = heterozygous familial hypercholesterolemia | HoFH = homozygous familial hypercholesterolemia | HTG = hypertriglyceridemia | Lp(a) = lipoprotein (a); | PCSK9 = Proprotein convertase subtilisin/kexin type 9 interfering RNA | siRNA = small;

Subscribe

Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.